Pipeline & Technology
Attovia is innovating breakthrough medicines for disease areas with high unmet need, including dermatology, gastroenterology/IBD, and other immune-mediated diseases.
Using our proprietary ATTOBODY™ platform, we design novel multispecifics that inhibit two, three, or even four disease-driving pathways—within a single molecule.
Pipeline & Technology
Attovia is innovating breakthrough medicines for disease areas with high unmet need, including dermatology, gastroenterology/IBD, and other immune-mediated diseases.
Using our proprietary ATTOBODY™ platform, we design novel multispecifics that inhibit two, three, or even four disease-driving pathways—within a single molecule.
Dermatology
| PROGRAM | INDICATION | DISCOVERY | IND ENABLING | PHASE 1 |
|---|---|---|---|---|
|
Chronic pruritus |
|
||
| Lorem ipsum dolor sit amet, consectetur adipiscing elit. Pellentesque in dignissim dolor. Sed a ornare augue. Fusce tincidunt ut tellus et fermentum. | ||||
|
Inflammatory skin disease |
|
||
Dermatology
| Program | Indication |
|---|---|
|
Chronic pruritus |
|
|
|
| Phase 1 | |
|
Inflammatory skin disease |
|
|
|
| Phase 1 | |
Gastroenterology
| PROGRAM | INDICATION | DISCOVERY | IND ENABLING | PHASE 1 |
|---|---|---|---|---|
|
IBD |
|
||
Gastroenterology
| PROGRAM | INDICATION |
|---|---|
|
IBD |
|
|
|
| IND ENABLING | |
Immune-mediated Disease
| PROGRAM | INDICATION | DISCOVERY | IND ENABLING | PHASE 1 |
|---|---|---|---|---|
|
Multispecifics |
|
||
Immune-mediated Disease
| PROGRAM | INDICATION |
|---|---|
|
Multispecific |
|
|
|
| DISCOVERY | |
Unleashing the power of ATTOBODY technology to develop new breakthrough medicines
ATTOBODIES utilize spatial positioning technology to achieve biparatopic target engagement. The biparatopic binding mode of ATTOBODIES results in ultra-high affinity, which translates to best-in-class potency in biologic activity. ATTOBODIES offer unconstrained engineering, making them an ideal modality for the development of multispecific biologics. The high-throughput, evolution-based ATTOBODY discovery platform delivers a high degree of diversity at industry-leading speed, accelerating and de-risking therapeutics development, offering the potential to become the next-generation modality of choice.
